Roivant drug delivers mid-stage results, Moonwalk raises funds to develop longer-lasting obesity drugs, and more biotech news ANDREW YATES/AFP via Getty Images Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we delve into how an FDA approval paradoxically complicated access to Revolution Medicines’ new pancreatic cancer drug for some patients, see standout mid-stage results for Roivant’s pulmonary hypertension drug, and more. Hope you had a lovely long weekend! Estoy trabajando en este Readout de la Biblioteca Vasconcelos en la CDMX. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Meghana Keshavan covers biotech and contributes to The Readout newsletter.
STAT+: FDA approves AstraZeneca breast cancer drug
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.